BioCryst Pharmaceuticals, Inc. (BCRX) Posts Q3 Loss of $0.32, Sales Miss Expectations
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $10.00 +4.71%
EPS Growth %: -13.3%
Financial Fact:
Net loss: -11.53M
Today's EPS Names:
DTGI, CRMT, STZ, More
EPS Growth %: -13.3%
Financial Fact:
Net loss: -11.53M
Today's EPS Names:
DTGI, CRMT, STZ, More
Join SI Premium – FREE
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q3 EPS of ($0.32), $0.06 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $5.25 million versus the consensus estimate of $6.84 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioCryst Pharma (BCRX) PT Raised to $17 at Jefferies
- BlackBerry (BB) Tops Q1 EPS by 1c, Offers Guidance
- Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
